EBS:NYE-Emergent Biosolutions Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 8.96

Change

+0.19 (+2.17)%

Market Cap

N/A

Volume

0.85M

Analyst Target

USD 112.29
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-05 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

+0.09 (+0.05%)

USD 85.62B
RDY Dr. Reddy’s Laboratories Ltd..

-59.38 (-80.25%)

USD 63.63B
TAK Takeda Pharmaceutical Co Ltd A..

+0.17 (+1.21%)

USD 44.45B
HLN Haleon plc

+0.01 (+0.10%)

USD 43.99B
CTLT Catalent Inc

-0.21 (-0.36%)

USD 10.78B
ELAN Elanco Animal Health

+0.11 (+0.88%)

USD 6.18B
BHC Bausch Health Companies Inc

+0.43 (+4.64%)

USD 3.56B
AMRX Amneal Pharmaceuticals, Inc. C..

-0.16 (-1.90%)

USD 2.55B
CPHI China Pharma Holdings Inc

-0.01 (-3.80%)

USD 4.03M
YCBD cbdMD Inc

-0.01 (-2.17%)

USD 2.11M

ETFs Containing EBS

XB4A:F Xtrackers ATX UCITS ETF 1.. 19.81 % 0.00 %

+0.44 (+-0.78%)

USD 0.04B
EBNK:CA Evolve European Banks Enh.. 5.06 % 0.00 %

-0.09 (-0.78%)

CAD 3.94M
EMUM:SW iShares MSCI EMU Mid Cap .. 1.83 % 0.00 %

N/A

USD 0.13B
LDEG:LSE L&G Quality Equity Divide.. 1.30 % 0.00 %

-0.10 (-0.78%)

N/A
EL43:XETRA Deka MSCI Europe MC UCITS.. 0.96 % 0.00 %

+0.06 (+-0.78%)

USD 0.02B
PRFZ Invesco FTSE RAFI US 1500.. 0.00 % 0.39 %

+0.82 (+-0.78%)

USD 2.56B
IS3H:F iShares IV Public Limited.. 0.00 % 0.00 %

+0.28 (+-0.78%)

N/A
IS3H:XETRA iShares MSCI EMU Mid Cap .. 0.00 % 0.00 %

+0.44 (+-0.78%)

USD 0.13B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 273.33% 87% B+ 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 273.33% 87% B+ 95% A
Trailing 12 Months  
Capital Gain 279.66% 87% B+ 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 279.66% 87% B+ 95% A
Trailing 5 Years  
Capital Gain -83.71% 14% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -83.71% 14% F 4% F
Average Annual (5 Year Horizon)  
Capital Gain -30.45% 7% C- 1% F
Dividend Return -30.45% 7% C- 1% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 70.32% 27% F 12% F
Risk Adjusted Return -43.30% 13% F 6% D-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector